If you are finally ready to break free from tobacco, Methodist Hospital offers the knowledge, techniques and support you need through a medically monitored QuitSmart-Chantix study.
The QuitSmart program, developed by Duke University Medical Center, has been shown to be at least twice as effective as other smoking cessation programs, yet takes just three class sessions. Participants enrolled in Methodist’s QuitSmart program will now have the option to participate in a supervised study of the smoking cessation medication Chantix.
FDA-approved Chantix has been prescribed to more than 5.5 million Americans and is currently in use in over 70 countries. Clinical studies have shown smoking cessation success for 44 percent of patients who used Chantix and received counseling over a 12-week period, versus success for 18 percent of patients given a placebo and counseling.
Chantix is not for everyone. Possible side effects include:
• Bad dreams
• Nausea
• Gastrointestinal symptoms
• Suicide ideation
Candidates will be screened for eligibility. The study is not open to those with kidney disease, pregnancy, mental illness, or to those who use insulin, asthma medications or anti-coagulants.
Eligible candidates are required to have an evaluation by psycho-oncologist Jane Theobald, MD. If cleared by Dr. Theobald, participants will receive their first month’s prescription of Chantix (a $100 value) free from Methodist Estabrook Cancer Center. Participants will be monitored weekly for the first month of Chantix use, then monthly.
For more information or registration, call (402) 354-5237.
This program is supported by Methodist Hospital Foundation.
